Xtant Medical Launches New Synthetic Bone Graft, nanOss Strata, for Enhanced Healing
The new graft material is designed for improved integration with patients' tissues, and it's available through distributors now.
Key findings
- Xtant Medical has launched nanOss Strata, a new synthetic bone graft in its nanOss product line.
- The graft is made from hydroxycarbonapatite (HCA), which the company says is more soluble than traditional hydroxyapatite (HA).
- nanOss Strata comes in preformed strips and prehydrated, moldable grafts, and is being sold through Xtant’s distribution network.
Stay Ahead in Regenerative Medicine
Thanks! Your signup has been saved.
Xtant Medical Holdings has commercially launched nanOss Strata, a next-generation synthetic bone graft in the company’s nanOss line.
What is nanOss Strata
nanOss Strata is manufactured from hydroxycarbonapatite (HCA), which Xtant says has higher solubility than traditional hydroxyapatite (HA), a commonly used synthetic bone graft material. According to the company, increased solubility can improve graft bioactivity (how the material interacts with biological tissue), supporting integration and remodeling with surrounding bone during healing.
It’s designed to closely mimic human bone and increase surface area, thereby improving osteoconductivity (the ability of a material to support bone growth along its surface) and stimulating the patient’s cellular activity on the graft’s surface after implantation.
Product formats
nanOss Strata is available in:
- Compression-resistant preformed strips
- Prehydrated moldable grafts
Xtant says both options are sterile, moldable, and designed to absorb blood and other biologic fluids quickly.
Sean Browne, President and CEO of Xtant Medical, stated, “By building on the clinical success of our nanOss products, Strata further demonstrates our commitment to innovation in regenerative medicine. We are excited to introduce this new technology to help our surgeon customers improve the surgical outcomes of their patients.”
nanOss Strata is now accessible through its nationwide distribution network.
Company snapshot
Xtant Medical Holdings is a medical technology company that designs and commercializes orthobiologics and spinal implant systems, with products serving markets including wound care and sports medicine. More information: www.xtantmedical.com.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
Similar stories
Made Scientific Selected to Manufacture Columbia University’s NOVAKnee, a 3D Printed Knee Replacement Made of Stem Cells and Scaffolds
BioStem Technologies Receives 5 Patents for Placental Allografts
Kangstem Publishes Promising Phase 1 Results for Cord-Blood Derived Stem Cell Therapy in Knee Osteoarthritis, Post-MRI Data Suggest Potential Cartilage Regeneration
Royal Biologics and Jellagen Bringing Jellyfish-Derived Collagen Type Zero to the US Regenerative Medicine MarketEditor’s Picks
Century Therapeutics Reports Sustained Glucose Control With iPSC-Derived Islets in Diabetic Mice, IND Soon
Umbilical Cord Mesenchymal Stem Cell Injections Lower Pain Scores More Than Hyaluronate in 50-Patient Severe Knee Osteoarthritis Trial
Stempeutics Nabs US Patent for Osteoarthritis Treatment Combining Bone Marrow Stem Cells and Hyaluronic Acid
Inside Cellular Intelligence: The Zuck-Backed AI Company That Acquired Novo’s Parkinson’s Cell Therapy
